Evaluation of Serologic Changes of IgG and IgM Antibodies Associated with SARS-COV-2 in Cancer Patients: A Cohort Seroprevalence Study

Arab, Mohammad; Teymoordash, Somayyeh Noei; Talayeh, Maryam; Ghavami, Behnaz; Javadi, Alireza; Nouri, Behnaz

doi:10.31557/apjcp.2021.22.6.1667

Cited by 4 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This rate was similar to another report from Iran where 4 out of 7 patients with cancer died due to COVID-19 ( Aznab, 2020 ). Asymptomatic infection detected by serological testing was reported in one study in Iran, conducted by Arab et al (2021) .…”

Section: High-risk Populationmentioning

confidence: 96%

Prognosis of COVID-19 in the middle eastern population, knowns and unknowns

Dandachi

Aljabr

2022

Front. Microbiol.

View full text Add to dashboard Cite

Since its emergence in China in 2019, the SARS-CoV-2 virus has affected all countries worldwide. The virus is easily transmitted from one person to another via infected aerosols or contaminated surfaces. Unlike its counterparts, the prognosis of COVID-19 ranges from asymptomatic to critical disease or death. Several factors play a role in determining the severity of the disease in infected patients. Among others, is the pre-existence of an underlying medical condition such as diabetes, cancer, and others. Furthermore, although children are less prone to the severe form of the COVID-19 disease, they require attention due to the report of many atypical presentations of the infection, post-asymptomatic exposure. In the Middle East, little is known about the prognosis of the SARS-CoV-2 infection in high-risk categories, notably patients with diabetes, cancer, and pregnant women. The aim of this review is to summarize the current knowledge about this group of population in the middle eastern region as well as to highlight the gap in the literature. We have found that the majority of the papers were from the Gulf countries. Although, few studies were conducted; high-risk patients appear to have an increased risk of morbidity and mortality from COVID-19 compared to their counterparts. Higher levels of inflammatory markers, C-reactive protein, erythrocyte sedimentation rate, D-dimer, and ferritin levels were also observed. Children are often asymptomatic or present with atypical presentations. More studies should be conducted to determine the clinical biomarkers of COVID-19 in high-risk categories to help in patient risk stratification and management in the middle eastern population.

show abstract

Section: High-risk Populationmentioning

confidence: 96%

Prognosis of COVID-19 in the middle eastern population, knowns and unknowns

Dandachi

Aljabr

2022

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…42 Nevertheless, even though such decreased anti-SARS-CoV-2 antibodies were not detected in asymptomatic COVID-19 cancer patients, more clinical studies are mandated to better understand this difference in asymptomatic patients since they play an essential role in the COVID-19 transmission chain. 43 In summary, the unprecedented burden of COVID-19 on healthcare systems worldwide has a significant impact on cancer care. First, despite limited data, cancer patients seem to be more susceptible to the more catastrophic outcomes from the infection, including increased need for mechanical ventilation 6 and mortality rates 37,[44][45][46][47] (Table 1).…”

Section: Oncologists During the Covid -19 Pandemicmentioning

confidence: 99%

Challenges posed by COVID‐19 in cancer patients: A narrative review

et al. 2021

View full text Add to dashboard Cite

A novel coronavirus, or severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), was identified as the causative agent of coronavirus disease 2019 (COVID‐19). In early 2020, the World Health Organization declared COVID‐19 the sixth public health emergency of international concern. The COVID‐19 pandemic has substantially affected many groups within the general population, but particularly those with extant clinical conditions, such as having or being treated for cancer. Cancer patients are at a higher risk of developing severe COVID‐19 since the malignancy and chemotherapy may negatively affect the immune system, and their immunocompromised condition also increases the risk of infection. Substantial international efforts are currently underway to develop specific methods for diagnosing and treating COVID‐19. However, cancer patients’ risk profiles, management, and outcomes are not well understood. Thus, the main objective of this review is to discuss the relevant evidence to understand the prognosis of COVID‐19 infections in cancer patients more clearly, as well as helping to improve the clinical management of these patients.

show abstract